Surgery

You are here

Clinical Trials

The Department of Surgery doesn’t just excel in the operating room. Through our extensive and innovative research programs, we are also focused on the development of new techniques and therapies that promote better outcomes and improve the quality of life for patients following surgery. 

As part of that goal, the department’s surgeons are involved in groundbreaking clinical trials. In addition to their research value, clinical trials may also give patients access to new treatments that are not available anywhere else.

Learn more about our current clinical trials below or visit the Joint Clinical Trials Office at Weill Cornell Medicine and NewYork-Presbyterian.

The purpose of this study is to find out about the safety and efficacy of PTG‐100 for the treatment of moderately to severe active ulcerative colitis, which is an inflammatory bowel disease (IBD) in which patients have bloody diarrhea, abdominal cramps and fatigue. 

Key Inclusion / Exclusion Criteria:

   - Male and female subjects age 18 to 80 years, inclusive 
   - Diagnosis of UC for at least 2 months prior to screening 
   - Detailed eligibility will be reviewed when you contact the study team 

The purpose of this research study is to compare the effects of the investigational study drugs, PF-06651600 and PF-06700841, with placebo to find out which is better for treating UC. 

Key Inclusion / Exclusion Criteria:

- Men and women 18 Years to 70 Years (Adult, Senior).
- Diagnosis of ulcerative colitis for greater than/equal to 4 months.
- Moderate to severe active ulcerative colitis.
- Inadequate response to, loss of response to, or intolerance to at least one conventional therapy for UC. 

Exclusion Criteria: 
- Pregnant or breastfeeding
- Clinical findings suggestive of Crohn's Disease 
- History of bowel surgery within 6 months 

    

Cardiac amyloid is a condition in which abnormal protein deposits within the heart. Patients with cardiac amyloid are at increased risk for clinical symptoms such as shortness of breath, fatigue, heart pain, or even death, possibly due to damaging effects of amyloid protein on the heart.

Key Inclusion / Exclusion Criteria:
  • Cardiac amyloid
  • Detailed criteria will be reviewed with study team

Currently, patients receiving a transplanted kidney are required to take life-long immunosuppressive medications to prevent rejection of the transplanted kidney. These medications carry substantial side effects.

Key Inclusion / Exclusion Criteria:

Inclusion

  • Planned recipient of a first kidney allograft from an HLA-matched, living related donor.
  • Age greater than or equal to 18 and less than or equal to 65 years at the time of providing informed consent.
  • Single solid organ recipient (kidney only).
  • ABO compatibility with donor
  • Able and willing to fully comply with all study procedures and restrictions.

Exclusion 

  • Underlying kidney disease with a high risk of disease recurrence in the transplanted kidney
  • History of HUS, atypical HUS, or TTP.
  • Is taking immunosuppressive therapy [eg, glucocorticoids, cyclosporine, mycophenolate, tumor necrosis factor (TNF) inhibitors] for multiple sclerosis, systemic lupus erythematosus, rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, or other acute or chronic condition.
  • Tests confirmed positive for HIV-1/2, human T-cell lymphotropic virus (HTLV)-I/II, West Nile Virus, HBV, HCV ,T. cruzi, or syphilis. Epstein-Barr Virus (EBV)- positive donors will be excluded if the prospective transplant recipient is EBV naïve. 
  • History of infection with Zika virus (ZIKV) in the past 6 months

This clinical trial is for men and women with advanced urothelial cancer. The purpose of this study is to compare the effects of an investigational drug called erdafitinib to those of docetaxel or vinflunine (chemotherapy) and of pembrolizumab (immunotherapy).

Key Inclusion / Exclusion Criteria:
  • Men and women age 18 and older 
  • Urothelial cancer with specific gene mutations 
  • One previous treatment for metastatic disease (disease which has spread to other parts of the body) 
  • Detailed eligibility reviewed when you contact the study team 

This clinical trial is for men and women who have been diagnosed with NonAlcoholic Steatohepatitis (NASH) and liver fibrosis (damaged/scarred liver tissue). Due to NASH, the liver is swollen and damaged because of a buildup of fat in the liver.

Key Inclusion / Exclusion Criteria:
  • Men and women who are 18 years of age and older
  • Must be diagnosed with NASH and liver scarring
  • Detailed eligibility reviewed when you contact the study team

This clinical trial is for males and females with veno-occlusive disease who are scheduled to undergo allogeneic or autologous hematopoietic stem cell transplant (HSCT) and are at high risk or very high risk of developing veno-occlusive disease (VOD). The medicines that are rec

Key Inclusion / Exclusion Criteria:

   - Males and females age 18 through 65
   - Patient must be scheduled to undergo allogeneic or autologous hematopoietic stem cell transplant (HSCT) 
   - Detailed eligibility will be reviewed when you contact the study team.

The primary objective of this trial is to evaluate the potential of dalcetrapib to reduce cardiovascular morbidity and mortality (cardiovascular death, resuscitated cardiac arrest, non-fatal myocardial infarction (MI) and non-fatal stroke) in subjects with a documented recent acute coronary

Key Inclusion / Exclusion Criteria:

- Subjects with the appropriate genetic background and recently hospitalized for ACS (between 1 and 3 months). 

- Male and female subjects age 45 years and over at Visit 1. 

- AA genotype variant in the ADCY9 gene. 

Detailed eligibility discussed when you contact the study team.

DO YOU SUFFER FROM PAIN ASSOCIATED WITH BONE METASTASES OR MULTIPLE MYELOMA?

If so, you may be eligible to participate in a research study being conducted at Weill Cornell Medical College.

Key Inclusion / Exclusion Criteria:
  • Men & Women 18 years and older
  • Diagnosed with bone metastases or multiple myeloma suffering from bone pain and for whom radiation therapy is not an alternative
  • Other criteria to be discussed with your doctor or the research team

This clinical trial is for men and women with high-grade gliomas. Glucose (sugar) is thought to be a contributor to tumor growth.

Key Inclusion / Exclusion Criteria:
  • Open to men and women above the age of 18 who have been diagnosed with high-grade gliomas.
  • Participants must not have recurrent disease, must not have been exposed to bevacizumab, and cannot be taking insulin or other oral hypoglycemic.
  • Detailed eligibility reviewed when you contact the study team. 

Find a Physician

Surgical Services
Weill Cornell Medicine Surgery

Visit our Surgery YouTube channel to view our video library.